Effects of Olopatadine Hydrochloride, a Histamine <svg style="vertical-align:-4.50008pt;width:24.775px;" id="M1" height="20.5625" version="1.1" viewBox="0 0 24.775 20.5625" width="24.775"  xmlns="http://www.w3.org/2000/svg">
	<g transform="matrix(1.25,0,0,-1.25,0,20.5625)">
		<g transform="translate(72,-55.55)">
			<text transform="matrix(1,0,0,-1,-71.95,60.08)">
				<tspan style="font-size: 17.93px; " x="0" y="0">H</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-59,55.6)">
				<tspan style="font-size: 12.55px; " x="0" y="0">𝟏</tspan>
			</text>

		</g>
	</g>
</svg> Receptor Antagonist, on Histamine-Induced Skin Responses

<table>Inhibitory effects of anti-histamines on VAS values of histamine-induced itching sensation after histamine iontophoresis (<svg height="7.9499998" id="M9" style="vertical-align:-0.1638pt" version="1.1" viewbox="0 0 8.6625004 7.9499998" width="8.6625004" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><path d="M495 86q-46 -47 -87 -72.5t-63 -25.5q-43 0 -16 107l49 210q7 34 8 50.5t-3 21t-13 4.5q-35 0 -109.5 -72.5t-115.5 -140.5q-21 -75 -38 -159q-50 -10 -76 -21l-6 8l84 340q8 35 -4 35q-17 0 -67 -46l-15 26q44 44 85.5 70.5t64.5 26.5q35 0 10 -103l-24 -98h2
q42 56 97 103.5t96 71.5q46 26 74 26q9 0 16 -2.5t14 -11.5t9.5 -24.5t-1 -44t-13.5 -68.5q-30 -117 -47 -200q-4 -19 -3.5 -25t6.5 -6q21 0 70 48z" id="x1D45B"></path></g>
</svg> = 10).  Results are presented as mean ± SE. <svg height="13.75" id="M10" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 7.7375002 13.75" width="7.7375002" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.012,-0,0,-.012,.062,5.525)"><path d="M471 153q-22 -15 -61 -13q-25 31 -45.5 49.5t-56.5 41.5q4 -71 28 -134q-17 -33 -42 -46q-24 12 -42 46q24 63 28 134q-36 -23 -56.5 -41.5t-45.5 -49.5q-36 -2 -61 13q0 28 19 59q65 10 130 43q-65 33 -130 43q-19 31 -19 59q22 15 61 13q25 -31 45.5 -49.5t56.5 -41.5
q-4 71 -28 134q17 33 42 46q24 -12 42 -46q-24 -63 -28 -134q36 23 56.5 41.5t45.5 49.5q36 2 61 -13q0 -28 -19 -59q-65 -10 -130 -43q65 -33 130 -43q19 -31 19 -59z" id="x2217"></path></g>
</svg><i>P </i>&lt;  .05, <svg height="13.75" id="M11" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 14.7125 13.75" width="14.7125" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.012,-0,0,-.012,.062,5.525)"><path d="M471 153q-22 -15 -61 -13q-25 31 -45.5 49.5t-56.5 41.5q4 -71 28 -134q-17 -33 -42 -46q-24 12 -42 46q24 63 28 134q-36 -23 -56.5 -41.5t-45.5 -49.5q-36 -2 -61 13q0 28 19 59q65 10 130 43q-65 33 -130 43q-19 31 -19 59q22 15 61 13q25 -31 45.5 -49.5t56.5 -41.5
q-4 71 -28 134q17 33 42 46q24 -12 42 -46q-24 -63 -28 -134q36 23 56.5 41.5t45.5 49.5q36 2 61 -13q0 -28 -19 -59q-65 -10 -130 -43q65 -33 130 -43q19 -31 19 -59z" id="x2217"></path></g><g transform="matrix(.012,-0,0,-.012,7.047,5.525)"><path d="M471 153q-22 -15 -61 -13q-25 31 -45.5 49.5t-56.5 41.5q4 -71 28 -134q-17 -33 -42 -46q-24 12 -42 46q24 63 28 134q-36 -23 -56.5 -41.5t-45.5 -49.5q-36 -2 -61 13q0 28 19 59q65 10 130 43q-65 33 -130 43q-19 31 -19 59q22 15 61 13q25 -31 45.5 -49.5t56.5 -41.5
q-4 71 -28 134q17 33 42 46q24 -12 42 -46q-24 -63 -28 -134q36 23 56.5 41.5t45.5 49.5q36 2 61 -13q0 -28 -19 -59q-65 -10 -130 -43q65 -33 130 -43q19 -31 19 -59z" id="x2217"></path></g>
</svg><i>P </i>&lt;  .01, and <svg height="13.75" id="M12" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 21.700001 13.75" width="21.700001" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.012,-0,0,-.012,.062,5.525)"><path d="M471 153q-22 -15 -61 -13q-25 31 -45.5 49.5t-56.5 41.5q4 -71 28 -134q-17 -33 -42 -46q-24 12 -42 46q24 63 28 134q-36 -23 -56.5 -41.5t-45.5 -49.5q-36 -2 -61 13q0 28 19 59q65 10 130 43q-65 33 -130 43q-19 31 -19 59q22 15 61 13q25 -31 45.5 -49.5t56.5 -41.5
q-4 71 -28 134q17 33 42 46q24 -12 42 -46q-24 -63 -28 -134q36 23 56.5 41.5t45.5 49.5q36 2 61 -13q0 -28 -19 -59q-65 -10 -130 -43q65 -33 130 -43q19 -31 19 -59z" id="x2217"></path></g><g transform="matrix(.012,-0,0,-.012,7.047,5.525)"><path d="M471 153q-22 -15 -61 -13q-25 31 -45.5 49.5t-56.5 41.5q4 -71 28 -134q-17 -33 -42 -46q-24 12 -42 46q24 63 28 134q-36 -23 -56.5 -41.5t-45.5 -49.5q-36 -2 -61 13q0 28 19 59q65 10 130 43q-65 33 -130 43q-19 31 -19 59q22 15 61 13q25 -31 45.5 -49.5t56.5 -41.5
q-4 71 -28 134q17 33 42 46q24 -12 42 -46q-24 -63 -28 -134q36 23 56.5 41.5t45.5 49.5q36 2 61 -13q0 -28 -19 -59q-65 -10 -130 -43q65 -33 130 -43q19 -31 19 -59z" id="x2217"></path></g><g transform="matrix(.012,-0,0,-.012,14.032,5.525)"><path d="M471 153q-22 -15 -61 -13q-25 31 -45.5 49.5t-56.5 41.5q4 -71 28 -134q-17 -33 -42 -46q-24 12 -42 46q24 63 28 134q-36 -23 -56.5 -41.5t-45.5 -49.5q-36 -2 -61 13q0 28 19 59q65 10 130 43q-65 33 -130 43q-19 31 -19 59q22 15 61 13q25 -31 45.5 -49.5t56.5 -41.5
q-4 71 -28 134q17 33 42 46q24 -12 42 -46q-24 -63 -28 -134q36 23 56.5 41.5t45.5 49.5q36 2 61 -13q0 -28 -19 -59q-65 -10 -130 -43q65 -33 130 -43q19 -31 19 -59z" id="x2217"></path></g>
</svg><i>P </i>&lt;  .001 (olopatadine versus placebo); <svg height="15.5625" id="M13" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 8.8000002 15.5625" width="8.8000002" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.012,-0,0,-.012,.062,7.35)"><path d="M624 398l-8 -50h-120l-40 -185h112l-8 -50h-115l-52 -239h-59l51 239h-148l-52 -239h-59l53 239h-126l9 50h128l41 185h-121l8 50h124l47 214h59l-48 -214h149l46 214h59l-47 -214h117zM439 348h-148l-40 -185h147z" id="x23"></path></g>
</svg><i>P </i>&lt;  .05, <svg height="15.5625" id="M14" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 16.862499 15.5625" width="16.862499" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.012,-0,0,-.012,.062,7.35)"><path d="M624 398l-8 -50h-120l-40 -185h112l-8 -50h-115l-52 -239h-59l51 239h-148l-52 -239h-59l53 239h-126l9 50h128l41 185h-121l8 50h124l47 214h59l-48 -214h149l46 214h59l-47 -214h117zM439 348h-148l-40 -185h147z" id="x23"></path></g><g transform="matrix(.012,-0,0,-.012,8.118,7.35)"><path d="M624 398l-8 -50h-120l-40 -185h112l-8 -50h-115l-52 -239h-59l51 239h-148l-52 -239h-59l53 239h-126l9 50h128l41 185h-121l8 50h124l47 214h59l-48 -214h149l46 214h59l-47 -214h117zM439 348h-148l-40 -185h147z" id="x23"></path></g>
</svg><i>P </i>&lt;   .01 (olopatadine versus fexofenadine).</table>

Dermatology Research and Practice

fig2

Figure 2

Figure 2: Effects of Olopatadine Hydrochloride, a Histamine <svg style="vertical-align:-4.50008pt;width:24.775px;" id="M1" height="20.5625" version="1.1" viewBox="0 0 24.775 20.5625" width="24.775"  xmlns="http://www.w3.org/2000/svg">
	<g transform="matrix(1.25,0,0,-1.25,0,20.5625)">
		<g transform="translate(72,-55.55)">
			<text transform="matrix(1,0,0,-1,-71.95,60.08)">
				<tspan style="font-size: 17.93px; " x="0" y="0">H</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-59,55.6)">
				<tspan style="font-size: 12.55px; " x="0" y="0">𝟏</tspan>
			</text>

		</g>
	</g>
</svg> Receptor Antagonist, on Histamine-Induced Skin Responses 

Figure 2 | Effects of Olopatadine Hydrochloride, a Histamine 
	
		
			
				H
			

			
				𝟏
			

		
	
 Receptor Antagonist, on Histamine-Induced Skin Responses 

Dermatology Research and Practice

Effects of Olopatadine Hydrochloride, a Histamine H 𝟏 Receptor Antagonist, on Histamine-Induced Skin Responses

Figure 2

Effects of Olopatadine Hydrochloride, a Histamine Receptor Antagonist, on Histamine-Induced Skin Responses